Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama City, Kanagawa, Japan.
Department of Gastroenterological surgery, Yokohama Municipal Citizen's Hospital, Yokohama City, Kanagawa, Japan.
Ann Surg Oncol. 2022 Sep;29(9):5885-5891. doi: 10.1245/s10434-022-11939-w. Epub 2022 Jun 28.
Prophylactic splenectomy for hilar lymph node (#10) dissection has shown no survival benefit for patients with proximal advanced gastric cancer that does not invade the greater curvature. However, the survival benefit of prophylactic splenectomy for proximal advanced gastric cancer invading the greater curvature side, particularly for clinically negative #10 lymph node metastasis (#10[-]) cases remains controversial.
This multi-institutional retrospective study enrolled 146 consecutive patients with proximal advanced gastric cancers invading the greater curvature side with clinical #10(-) who underwent R0 total gastrectomy. For 33 of these patients, splenectomy was performed, and the remaining 113 underwent spleen-preservation gastrectomy. Short- and long-term results were compared between the splenectomy and spleen-preservation groups, with the incidence of #10 metastasis in the splenectomy group and recurrence in the spleen-preservation group compared.
In the splenectomy group, longer operative time, greater blood loss, more frequent postoperative abdominal infection, and longer hospital stay were observed than in the spleen-preservation group. The two groups exhibited no differences in median relapse-free survival time (31.1 vs 59.8 months; P = 0.684) or median overall survival time (64.9 vs 65.1 months; P = 0.765). The pathologic #10 lymph node metastasis rate was 3% in the splenectomy group, and the #10 lymph node recurrence rate was 2.7% in the spleen-preservation group.
Prophylactic splenectomy showed more frequent postoperative morbidities and a longer hospital stay than spleen preservation, without any long-term survival benefits.
对于未侵犯大弯侧的近端进展期胃癌行预防性脾切除术联合肝门部淋巴结(#10)清扫并未显示出生存获益。然而,对于侵犯大弯侧的近端进展期胃癌行预防性脾切除术的生存获益,特别是对于临床阴性#10 淋巴结转移(#10[-])病例,仍存在争议。
本多中心回顾性研究纳入了 146 例接受 R0 全胃切除术且侵犯大弯侧、临床#10(-)的近端进展期胃癌患者。其中 33 例患者接受了脾切除术,其余 113 例患者接受了保留脾脏的胃切除术。比较了脾切除术和保留脾脏组的短期和长期结果,并比较了脾切除术组的#10 转移发生率和保留脾脏组的复发率。
脾切除术组的手术时间较长、出血量较大、术后腹部感染发生率较高、住院时间较长。两组患者的中位无复发生存时间(31.1 个月 vs 59.8 个月;P=0.684)和中位总生存时间(64.9 个月 vs 65.1 个月;P=0.765)无差异。脾切除术组的病理#10 淋巴结转移率为 3%,保留脾脏组的#10 淋巴结复发率为 2.7%。
预防性脾切除术与保留脾脏相比,术后并发症更常见,住院时间更长,但无长期生存获益。